NewLink Genetics Corporation - Product Pipeline Review - Q4 2010

Global Markets Direct, December 2010, Pages: 33

NewLink Genetics Corporation – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “NewLink Genetics Corporation - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- NewLink Genetics Corporation - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of NewLink Genetics Corporation human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of NewLink Genetics Corporation with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the NewLink Genetics Corporation’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate NewLink Genetics Corporation’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of NewLink Genetics Corporation in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the NewLink Genetics Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with NewLink Genetics Corporation.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of NewLink Genetics Corporation and identify potential opportunities in those areas.

List of Tables
List of Figures
NewLink Genetics Corporation Snapshot
NewLink Genetics Corporation Overview
Key Information
Key Facts
NewLink Genetics Corporation – Research and Development Overview
Key Therapeutic Areas
NewLink Genetics Corporation – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
NewLink Genetics Corporation – Pipeline Products Glance
NewLink Genetics Corporation – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
NewLink Genetics Corporation Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
NewLink Genetics Corporation – Drug Profiles
HyperAcute-Pancreas
Product Description
Mechanism of Action
R&D Progress
HyperAcute Lung Cancer Vaccine
Product Description
Mechanism of Action
R&D Progress
HyperAcute-Breast Cancer Vaccine
Product Description
Mechanism of Action
R&D Progress
HyperAcute-Melanoma
Product Description
Mechanism of Action
R&D Progress
HyperAcute-Prostate Cancer Vaccine
Product Description
Mechanism of Action
R&D Progress
D-1MT
Product Description
Mechanism of Action
R&D Progress
NewLink Genetics Corporation – Pipeline Analysis
NewLink Genetics Corporation – Pipeline Products by Therapeutic Class
NewLink Genetics Corporation Pipeline Products By Target
NewLink Genetics Corporation – Pipeline Products by Route of Administration
NewLink Genetics Corporation – Pipeline Products by Molecule Type
NewLink Genetics Corporation – Locations And Subsidiaries
Head Office
Recent Developments
Jun 07, 2010: NewLink Genetics Reports Positive Data From Phase II Trial Of HyperAcute-Pancreas Cancer Immunotherapy
Jun 06, 2010: NewLink Genetics' HyperAcute Immunotherapy Phase II Study Shows Promise In Disease Free And Overall Survival For Resectable Pancreatic Cancer
May 27, 2010: NewLink Initiates Pivotal Phase III Clinical Trial Of HyperAcute-Pancreas Immunotherapy For Resected Pancreatic Cancer
May 20, 2010: NewLink Genetics To Present Phase II Data Of HyperAcute-Pancreas Immunotherapy For Resected Pancreatic Cancer
Apr 19, 2010: NewLink Genetics Presents Positive Phase I/II Data On HyperAcute-Lung Cancer Immunotherapy
Apr 15, 2010: NewLink Genetics To Present Data On HyperAcute Lung Cancer Immunotherapy At American Association For Cancer Research Annual Meeting
Financial Deals Landscape
NewLink Genetics Corporation, Deals Summary, 2004 to 2010
NewLink Genetics Corporation Detailed Deal Summary
Venture Financing
NewLink Genetics Secures $30 Million In Series C Financing
NewLink Genetics Raises $7.5 Million In Series D Round Of Financing
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• eLEARNING - Global Strategic Business Report
• Charter Schools - Global Outlook
• Aerospace and Defense Industry - Global Strategic Business Report
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Education Services - Global Strategic Business Report
• Sports and Fitness Nutrition - Global Strategic Business Report
• North America – Smart Weapons Markets and Technologies Outlook – 2013-2020
• The Global UAV Payload Market 2012-2022
• Aerospace and Defense Industry - Global Outlook
• Defense Robotics - Global Strategic Business Report